

Drug therapy for bronchial asthma

Bronchodilators

1- β_2 agonists

A. Non-selective β -agonists (β_1, β_2): Adrenaline (used only in bronchial asthma due to anaphylactic shock)
 Selective β_2 agonists:
 ■ Short-acting: salbutamol, terbutaline (4-6 H)
 ■ Long acting: salmeterol and formoterol (12 H)

1) **Salbutamol**: Short acting beta2 agonist (SABA)
 ■ Selective stimulant of β_2 adrenergic receptors
 ■ Selective action on the bronchi
 ■ Given orally & by inhalation
 2) **Terbutaline**: Short acting beta2 agonist (SABA)
 ■ Like salbutamol but has a delayed onset of action

3) **Salmeterol** & **Formoterol**: long acting beta2 agonist (LABA)
 ■ Selective long-acting β_2 agonists
 ■ Given by inhalation for long-term prevention of bronchial asthma
 ■ Should be combined with inhaled corticosteroids to avoid tolerance

Adverse effects:
 ■ Tremors
 ■ Tachycardia: Arrhythmia may occur in patients with underlying cardiac diseases eg, ischemic heart disease
 ■ Tolerance
 ■ Hypokalemia
 Note: Adverse effects occur more frequently with oral preparations than with inhalation
 Note: Nebulizers provide more quantity of the drug than MDIs, so nebulized β_2 agonists can cause more adverse effect

3- Muscarinic (M) Antagonists

■ **Atropine** (tertiary amine) blocks bronchial M receptors, but it is not effective in bronchial asthma because:
 1. Cholinergic pathways play a minor role in the pathogenesis of bronchial asthma
 2. Non-selective effects:
 ■ Dryness of bronchial secretions
 ■ \downarrow Muco-ciliary function¹⁵

■ **Ipratropium bromide**:
 ✓ Quaternary ammonium derivative of atropine
 ✓ Minimal amounts are absorbed \rightarrow no systemic adverse effects
 ✓ More selective (causes bronchodilation without effects on sputum viscosity or ciliary function)
 ✓ No central effects
 ✓ Given by inhalation & can be combined with β_2 agonists
 ✓ Short-acting \rightarrow used 3-4 times daily

■ **Tiotropium** differs from **ipratropium** in the following
 ✓ Long-acting (given once/day)
 ✓ Given by inhalation
 ✓ Approved for treatment of COPD with no cardiac adverse effects

2- Methylxanthines (Aminophylline & Theophylline)

Mechanism of action:
 ■ PDE inhibitors \rightarrow \uparrow cAMP which causes redistribution of intracellular Ca^{2+} \rightarrow bronchodilatation
 ■ Block adenosine receptors \rightarrow bronchodilatation
 ■ Improve diaphragmatic contraction & ventilatory response to hypoxia
 ■ \uparrow mediators release from mast cell

Pharmacokinetics:
 ■ Theophylline is absorbed by all routes
 ■ Distributed all over the body & passes BBB and placental barrier
 ■ Metabolized in liver (by xanthine oxidase) into soluble methyluric acid (not precipitated in the joints \rightarrow not contraindicated in gout)
 ■ Narrow therapeutic window with low safety

Pharmacological actions:
 ■ Relaxation of the smooth muscle (bronchial, intestinal, biliary, ureteric and vascular smooth muscles "except cerebral blood vessels" \rightarrow vasodilatation and hypotension)
 ■ CVS: Direct: positive inotropic & chronotropic effects - VD (hypotension)
 Central: stimulation of CIC (bradycardia) & VMC (hypertension)
 ■ Large & rapid IV injection \rightarrow hypotension & arrhythmia.
 Precautions:
 ■ Monitoring of plasma level (to avoid toxicity)
 ■ Slow IV administration to avoid hypotension & arrhythmia

Note: **Roflumilast**
 ■ A selective PDE-4 inhibitor \rightarrow has selective action on airways & inflammatory cells \rightarrow fewer adverse effects than methylxanthines
 ■ Approved for treatment of COPD (chronic obstructive disease)

Anti-inflammatory drugs

1- Corticosteroids

Mechanism of action:
 ✓ \uparrow Synthesis of lipocortin \rightarrow \downarrow PLA₂ activity \rightarrow \downarrow arachidonic acid, PGs and LTs synthesis
 ✓ Immunosuppressive action (\downarrow antibody synthesis) & inhibition of Ag/Ab reaction & mast cell stabilization
 ✓ \uparrow Capillary permeability & reduce mucosal edema
 ✓ \uparrow Catecholamines effect through:
 ■ Block neuronal reuptake
 ■ \uparrow Methylation of noradrenaline to adrenaline

Uses in bronchial asthma:
 ✓ Prophylaxis (in between attacks)
 ✓ Repeated nocturnal asthma
 ✓ Acute severe asthma
 Preparations:
 A. Inhalation: beclomethasone, budesonide, fluticasone (long-acting)
 B. Parenteral: methylprednisolone, hydrocortisone, dexamethasone, ACTH
 C. Oral: prednisolone

Adverse effects:
 A. Inhalation:
 ✓ Oral moniliasis (treated by nystatin)
 ✓ Dysphonia due to weakness (myopathy) of adductor muscle of the cord
 B. Suppressive effects: adrenocortical suppression
 C. Cushing's syndrome (with the use of large doses of corticosteroids)
 D. Metabolic: hypokalemia, hyperglycemia, salt & water retention, weight gain and hypertension
 E. Cataract

3- Mast cell stabilizers

Members:
 1. **Disodium cromoglycate (Cromolyn sodium)**
 2. **Ketotifen**
 ✓ They are not bronchodilators
 ✓ So, they cannot relieve acute attacks of asthma
 ✓ They can be effective only if given before the exposure the antigen
 ✓ Mechanism: stabilization of mast cell membrane (possibly by blocking calcium influx) \rightarrow \downarrow release of allergic mediators eg, histamine & LTs

✓ They are useful chiefly for asthma prophylaxis, particularly children & young adults
 ✓ Ketotifen has additional antihistamine effect
 ✓ Route:
 ■ Disodium cromoglycate: inhalation
 ♦ It is also available as nasal spray for allergic rhinitis & as eye drops for allergic conjunctivitis
 ■ Ketotifen: oral administration
 ✓ Adverse effects:
 ■ Disodium cromoglycate:
 ♦ Local irritation: bronchospasm & cough
 ■ Ketotifen:
 ♦ Drowsiness

Supportive treatment

2- Leukotriene Antagonists

■ They include:
 1. LT receptor antagonists (**Montelukast** & **zafirlukast**)
 2. 5-LOX inhibitors (**zileuton**): \downarrow LTs synthesis
 ■ Pharmacokinetics:
 ✓ All members are given orally
 ✓ Zafirlukast absorption is affected by food
 ✓ They are metabolized by liver

■ Uses:
 ✓ prophylaxis of bronchial asthma especially aspirin-induced asthma
 ■ Adverse effects:
 ✓ Liver toxicity:
 ♦ Regular monitoring of liver transaminases is required if their levels exceeded 3-5 times the normal level, these drugs should be discontinued
 ♦ More reported with zileuton
 ✓ Systemic vasculitis (Churg-Strauss syndrome): rare

4-Omalizumab

✓ Selectively binds to human IGE \rightarrow inhibits IGE binding to its receptor on mast cells & basophils surface \rightarrow \downarrow release of inflammatory mediators
 ✓ It decreases severity and frequency of asthma exacerbations
 ✓ Used in patients resistant to conventional therapy (β_2 agonists & inhaled corticosteroids)
 ✓ Its use is limited by its high cost